GRTS

Gritstone bio, Inc.

0.76 USD
-0.00 (-0.45%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Gritstone bio, Inc. stock is down -7.63% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jun 17:55 15 Nov, 2024 1.00 CALL 1000 2586

About Gritstone bio, Inc.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for common solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine

  • JP Morgan
    Fri Jun 14, 10:47
    buy
    confirm
  • B. Riley
    Fri May 24, 09:22
    buy
    confirm